chf solutions is an early stage company focused on commercializing the aquadex flexflow system. our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. at chf solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address unmet clinical needs with the goal of benefiting patients, medical practitioners, and the broader healthcare community. if you are looking for a career where you can make difference we would like to hear from you. we are looking for highly skilled, highly motivated people who want to be part of a growing company where everything you do will matter. chf solutions is an equal opportunity/affirmative action employer committed to cultural diversity in the workplace.
Company profile
Ticker
NUWE
Exchange
Website
CEO
John L. Erb
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
CHF Solutions, Inc., Sunshine Heart, Inc.
SEC CIK
Corporate docs
Subsidiaries
Sunshine Heart Ireland Limited ...
IRS number
680533453
NUWE stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
17 May 24
DEFR14A
Revised proxy
17 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
PRER14A
Preliminary revised proxy
8 May 24
8-K
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
7 May 24
DEF 14A
Definitive proxy
30 Apr 24
8-K
Nuwellis Announces Pricing of $2.7 Million Public Offering
30 Apr 24
424B4
Prospectus supplement with pricing info
29 Apr 24
EFFECT
Notice of effectiveness
29 Apr 24
S-1/A
IPO registration (amended)
17 Apr 24
Transcripts
NUWE
Earnings call transcript
2024 Q1
7 May 24
NUWE
Earnings call transcript
2023 Q4
5 Mar 24
NUWE
Earnings call transcript
2023 Q3
7 Nov 23
NUWE
Earnings call transcript
2023 Q2
8 Aug 23
NUWE
Earnings call transcript
2023 Q2
8 Aug 23
NUWE
Earnings call transcript
2023 Q1
9 May 23
NUWE
Earnings call transcript
2022 Q4
28 Feb 23
NUWE
Earnings call transcript
2022 Q3
8 Nov 22
NUWE
Earnings call transcript
2022 Q2
9 Aug 22
NUWE
Earnings call transcript
2022 Q1
10 May 22
Latest ownership filings
SC 13G
S.H.N. Financial Investments Ltd.
6 May 24
SC 13G
INTRACOASTAL CAPITAL, LLC
3 May 24
4
Michael Kendrick McCormick
4 Jan 24
4
David McDonald
4 Jan 24
4
Archelle Georgiou Feldshon
4 Jan 24
3
David McDonald
1 Nov 23
3
Archelle Georgiou Feldshon
1 Nov 23
4
Robert Benjamin Scott
6 Sep 23
3
Robert Benjamin Scott
6 Sep 23
4
Michael Kendrick McCormick
5 Jun 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm |
Cash burn (monthly) | 800.00 k | 842.92 k | 1.58 mm | 1.55 mm | 954.00 k | 1.22 mm |
Cash used (since last report) | 1.27 mm | 1.34 mm | 2.52 mm | 2.47 mm | 1.52 mm | 1.95 mm |
Cash remaining | 127.51 k | 59.25 k | -1.12 mm | -1.07 mm | -117.44 k | -547.57 k |
Runway (months of cash) | 0.2 | 0.1 | -0.7 | -0.7 | -0.1 | -0.4 |
Institutional ownership, Q4 2023
1.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 9 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 184.00 k |
Total shares | 216.03 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bigger Capital Fund L P | 161.55 k | $184.00 k |
Lind Global Fund II | 54.48 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Archelle Georgiou Feldshon | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 11,365 | 7.84 k | 11,365 |
2 Jan 24 | David McDonald | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 11,365 | 7.84 k | 11,365 |
2 Jan 24 | Michael Kendrick McCormick | Nonstatutory Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 20,836 | 14.38 k | 20,836 |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
8 May 24
Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings
7 May 24
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
7 May 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
7 May 24
Crude Oil Edges Lower; UBS Shares Jump After Q1 Earnings
7 May 24
Press releases
Nuwellis Announces Closing of $2.7 Million Public Offering
30 Apr 24
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
30 Apr 24
Nuwellis Announces Pricing of $2.7 Million Public Offering
26 Apr 24
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
7 Mar 24
Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
22 Feb 24